BioNTech Stock Dips After BNT122-01 Trial Termination

BioNTech SE (NASDAQ:BNTX) shares are dropping Friday after the company announced it will terminate its Phase 2 clinical trial of autogene cevumeran in resected colorectal cancer. Here’s what you should know. BioNTech stock is feeling bearish pressure. What’s behind...